Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II

• US 8,445,535 B1
• Filed: 12/22/2004
• Issued: 05/21/2013
• Est. Priority Date: 05/01/2000
• Status: Active Grant

• Current Assignee: Cerecin, Inc.
• Original Assignee: Accela Incorporated (Piksel Incorporated)
• Inventors: Henderson, Samuel T
• Primary Examiner(s): Hui, San-Ming
• Assistant Examiner(s): CRUZ, KATHRIEN ANN
• Application Number:
  US11/021,920
• Time in Patent Office: 3,072 Days
• Field of Search: 514/557, 524/557
• US Class Current: 514/557
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/12 Ketones
• CPC Class Codes: A61K 31/20 having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
• CPC Class Codes: A61K 31/205 Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
• CPC Class Codes: A61K 31/215 of carboxylic acids
• CPC Class Codes: A61K 31/22 of acyclic acids, e.g. pravastatin
• CPC Class Codes: A61K 31/221 with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
• CPC Class Codes: A61K 31/23 of acids having a carboxyl group bound to a chain of seven or more carbon atoms
• CPC Class Codes: A61K 31/25 with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Methods and compositions for treating or preventing, the occurrence of senile dementia of the Alzheimer'"'"'s type, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of triglycerides or fatty acids with chain lengths between 5 and 12, to said patient at a level to produce an improvement in cognitive ability.

Claims

1. A method of treating loss of cognitive function in patients having Alzheimer'"'"'s disease or Mild Cognitive Impairment in a patient lacking ApoE4, comprising:

a) selecting a patient having Alzheimer'"'"'s disease or Mild Cognitive Impairment;

b) determining a patient'"'"'s apolipoprotein E genotype; and

c) providing an oral pharmaceutical composition comprising medium chain triglycerides to a patient having an absence of ApoE4 in an amount effective for the treating loss of cognitive function in patients having Alzheimer'"'"'s disease or Mild Cognitive Impairment,

whereby loss of cognitive function is treated.

2. The method of claim 1, wherein the oral composition is administered in a dosage unit such that the blood level of D-beta-hydroxybutyrate in the patient is raised to about 0.1 to 50 mM.

3. The method of claim 1, wherein the dosage unit causes hyperketonemia in the patient when the patient has a diet wherein carbohydrate intake is not restricted.

4. The method of claim 1, wherein said medium chain triglycerides are administered at a dose of about 0.01 g/kg/day to about 10 g/kg/day.

5. The method of claim 1, wherein the dosage unit is given in a single dose.

6. A method of treating loss of cognitive function in patients having Alzheimer'"'"'s disease or Mild Cognitive Impairment in a patient lacking ApoE4, comprising:

a) selecting a patient having Alzheimer'"'"'s disease or Mild Cognitive Impairment;

b) determining a patient'"'"'s apolipoprotein E genotype; and

c) providing an oral pharmaceutical composition comprising medium chain triglycerides to a patient having an absence of ApoE4 in an amount effective for the treating loss of cognitive function in patients having Alzheimer'"'"'s disease or Mild Cognitive Impairment, wherein the oral pharmaceutical composition is administered in a dosage unit such that the blood level of D-beta-hydroxybutyrate in the patient is raised to about 0.2 to 20 mM and wherein the dosage unit is given in a single dose,

whereby loss of cognitive function is treated.

7. The method of claim 6, wherein the oral pharmaceutical composition causes hyperketonemia in the patient when the patient has a diet wherein carbohydrate intake is not restricted.